NEWS
![[Edaily] C&R Research Led US FDA Approval Of ‘EYELEA’ Phase 3 IND Clinical Trial](https://www.cnrres.com/wp-content/uploads/2021/04/CR-CI_홈페이지-기사-업로드용-300x200.png)
[Edaily] C&R Research led US FDA approval of ‘EYELEA’ Phase 3 IND clinical trial
2024-04-17
C&R Research successfully carried out US FDA approval for the Phase 3 IND clinical trial of 'EYELEA' Biosimilar with Rophibio,…
[Yakup] C&R Research, Successfully completed US FDA medical device 510(k) approval work
2024-04-02
C&R Research (CEO Moon-Tae Yoon) successfully carried out the US FDA medical device 510(k) approval work, expanding business scope to…
[Edaily] Moon-Tae Yoon, CEO of C&R Research, collaborates with Kakao on CDISC clinical standardization… ‘Crossing the FDA Threshold’
2024-03-08
C&R Research, a contract research organization (CRO) is undergoing a complete overhaul of its clinical data collection method. They are…
[Edaily] Moon-Tae Yoon, CEO of C&R Research, “Three Clinical Contract Orders Confirmed in the United States… Considering Establishing European Branch”
2024-02-29
Moon-Tae Yoon, CEO of C&R Research (359090), is seeing success with his overseas expansion strategy. New orders are consistently increasing…
[Edaily] C&R Research achieves 55.1 Billion KRW in Revenue Last Year… Up by 13.7% Year-on-Year
2024-02-15
C&R Research (359090) announced its provisional performance, reporting a 13.7% increase in revenue and a 41.6% increase in net profit…